The Senolytic Stack 2026: Quercetin + Fisetin + SGLT2 Combined Protocol

Key Takeaways

• This protocol combines three mechanistically distinct senolytic approaches: Quercetin (BCL-xL inhibition), Fisetin (multi-mechanism flavonoid senolysis), and SGLT2 inhibitor (immune-mediated clearance).
• The 2025 Cell Reports Medicine henagliflozin trial demonstrated SGLT2 inhibitors function as indirect senolytics — opening a completely new senolytic mechanism.
• Pulsed dosing of Quercetin (1250mg x 2 days monthly) and Fisetin (1000mg x 3 days monthly) maximises senolytic activity while minimising off-target effects.
• Continuous low-dose SGLT2 inhibitor (5-10mg daily) provides ongoing immune surveillance enhancement.
• This is an advanced protocol — most appropriate for adults 50+ with established longevity-focused care.

The Senolytic Field in 2026

Cellular senescence has emerged as one of the most actionable hallmarks of aging. Senescent cells — dysfunctional "zombie cells" that accumulate with age — secrete inflammatory cytokines (SASP) that drive chronic inflammation, fibrosis, and tissue dysfunction. Clearing senescent cells has demonstrated:

• Extended healthspan in mice
• Improved physical function in human pilot trials (D+Q in IPF)
• Reduced inflammation markers
• Improved metabolic parameters
• Potential cognitive benefits

The field has evolved dramatically since the original Mayo Clinic D+Q protocols. Three approaches now exist:

1. Direct senolytics (Quercetin, Fisetin):

• Inhibit pro-survival pathways in senescent cells
• Trigger apoptosis selectively in senescent cells
• Pulsed dosing

2. Indirect senolytics (SGLT2 inhibitors):

• Don't kill senescent cells directly
• Enable immune system to recognise and clear them
• Continuous low-dose

3. Immune-supportive senotherapy (Urolithin A):

• Improves immune cell function
• Enhances natural senescent cell surveillance
• Continuous use

The 2026 senolytic stack combines mechanisms from these distinct approaches.

Quercetin

Component 1: Quercetin (Direct Senolytic)

Role: BCL-xL inhibition, direct senescent cell apoptosis Dose: 1250mg x 2 consecutive days, monthly cycling Form: Quercetin Phytosome or EMIQ for bioavailability

Quercetin emerged from Mayo Clinic research as a senolytic when combined with Dasatinib (D+Q protocol). At adequate doses, it inhibits BCL-xL — an anti-apoptotic protein that senescent cells depend on for survival.

The pulsed dosing rationale:

• Senescent cells are relatively quiescent
• Single high-dose pulses produce apoptosis
• Continuous low dosing doesn't achieve therapeutic plasma concentrations
• Monthly cycling allows cleared senescent cells to be replaced gradually

Practical protocol:

• Day 1: 1250mg Quercetin Phytosome
• Day 2: 1250mg Quercetin Phytosome
• Repeat every 30 days
• Take with fatty meal for absorption

The Dasatinib question: The complete D+Q protocol includes Dasatinib (prescription tyrosine kinase inhibitor). For full senolytic potency, both compounds together are superior to Quercetin alone.

With physician access:

• Add Dasatinib 100mg on each of the 2 dosing days
• Significantly enhances senolytic activity
• Established trial protocol

Without Dasatinib:

• Quercetin alone has weaker but measurable senolytic activity
• Substitute or add Fisetin for greater natural senolytic effect
• Recognised limitation but acceptable approach

Component 2: Fisetin (Natural Multi-Mechanism Senolytic)

Role: Multi-mechanism flavonoid senolysis Dose: 1000mg x 3 consecutive days, monthly cycling Form: Liposomal or standardised extract

Fisetin emerged as a potent natural senolytic in Yousefzadeh et al. (EBioMedicine, 2018). In screening assays, fisetin demonstrated greater senolytic activity than other natural compounds tested. The mechanism involves multiple pathways:

• PI3K/AKT pathway inhibition
• BCL-xL/BCL-2 modulation
• Autophagy induction
• Anti-inflammatory effects

Why fisetin matters:

• Stronger natural senolytic than Quercetin alone (without Dasatinib)
• Cleaner safety profile than D+Q
• OTC, no prescription required
• Can be used without medical supervision

Practical protocol:

• Day 1-3: 1000mg fisetin (liposomal preferred)
• Repeat every 30 days
• Take with fatty meal

Coordination with Quercetin:

• Stagger Quercetin and Fisetin pulses — don't combine them on same days
• Example: Quercetin days 1-2 of month, Fisetin days 15-17 of month
• This provides senolytic activity twice monthly with different mechanisms

Fisetin

Component 3: SGLT2 Inhibitor (Immune-Mediated Senolytic)

Role: Indirect senolysis via enhanced immune surveillance Dose: 5-10mg daily continuous (dapagliflozin or empagliflozin) Form: Pharmaceutical (prescription required in most jurisdictions)

This is the new addition to senolytic protocols based on 2024-2025 evidence:

Katsuumi et al. (Nature, 2024):

• SGLT2 inhibition reduces senescent cell burden in mice
• Mechanism: AICAR upregulation → PD-L1 downregulation on senescent cells → immune-mediated clearance
• Completely different from Quercetin/Fisetin mechanisms

Zhang et al. (Cell Reports Medicine, 2025):

• Henagliflozin 10mg daily for 26 weeks in humans
• 90.5% of participants showed telomere lengthening
• Significant granzyme B elevation (cytotoxic T cell function)
• No inflammation increase (targeted, not broad immune activation)

Why this is exciting:

• First daily-dosing senolytic mechanism
• Doesn't require pulsed dosing
• Multiple proven benefits beyond senolysis (cardiovascular, renal, metabolic)
• Targets senescent cells the direct senolytics may miss

Practical implementation:

• Dapagliflozin 5mg or 10mg daily
• Or empagliflozin 10mg daily
• Continuous use
• Requires prescription in most countries

For those without SGLT2 access:

• This component cannot be readily replaced
• Direct senolytics alone provide partial benefit
• Consider longevity physician for prescription access

Component 4 (Optional): Urolithin A

Role: Immune cell function support Dose: 500mg daily continuous Form: Mitopure or equivalent

The 2025 MitoImmune trial demonstrated Urolithin A improves immune cell function and reduces inflammation. This supports the immune surveillance mechanism of the SGLT2 inhibitor:

• SGLT2 inhibitor reveals senescent cells to immune system (PD-L1 down)
• Urolithin A enhances immune cell capacity to clear them
• Synergistic mechanism

This component is optional based on cost considerations (Urolithin A is premium-priced) but mechanistically valuable.

The Complete Protocol

Daily continuous:

• Dapagliflozin 5-10mg (morning)
• Urolithin A 500mg (morning, optional)
• Standard longevity foundation supplements

Monthly pulsed (alternate weeks):

Week 1 of month:

• Day 1: Quercetin Phytosome 1250mg (± Dasatinib 100mg if available)
• Day 2: Quercetin Phytosome 1250mg (± Dasatinib 100mg)

Week 3 of month:

• Day 1: Fisetin 1000mg
• Day 2: Fisetin 1000mg
• Day 3: Fisetin 1000mg

Weeks 2 and 4: Continuous components only, no pulsed senolytics

This provides senolytic activity through three distinct mechanisms while spacing the pulsed compounds to avoid additive off-target effects.

Prerequisites and Safety

This is an advanced protocol appropriate for specific situations:

Strong candidates:

• Adults 50+ with established baseline care
• Confirmed cardiovascular or metabolic risk factors
• Family history of premature aging-related disease
• Established work with longevity physician
• Sufficient resources for medication and monitoring

Pre-protocol assessment:

• Complete metabolic panel
• Lipid panel
• HbA1c
• hs-CRP, IL-6
• CBC with differential
• Kidney function (creatinine, eGFR)
• Liver function (ALT, AST)
• For SGLT2: rule out type 1 diabetes, severe renal impairment

Monitoring during protocol:

• Baseline and 3-month: above panel
• Watch for:
  • Excessive GI side effects on senolytic days
  • SGLT2-related infections (genital yeast, UTIs)
  • Volume status
  • Any new symptoms

When Not to Use This Protocol

Contraindications:

• Active pregnancy or breastfeeding
• Active cancer (senolytic effects on cancer biology complex)
• Active major infection
• Severe renal impairment (eGFR <30)
• Recent major surgery (use after recovery)
• Frailty syndrome (senolytic effects on frail individuals less well-studied)

Use caution:

• Adults under 40 (senescent cell accumulation lower)
• Type 1 diabetes (DKA risk with SGLT2)
• History of recurrent infections
• Multiple medications with potential interactions

Expected Effects Timeline

Weeks 1-4:

• Adaptation to SGLT2 inhibitor
• First Quercetin and Fisetin pulses
• Minor changes in inflammatory markers possible

Months 1-3:

• Measurable hs-CRP and IL-6 reductions in many users
• Body composition improvements (SGLT2-mediated)
• Subjective energy improvements

Months 3-6:

• More substantial inflammatory marker improvements
• Possible telomere changes (per Zhang 2025 timeline)
• Improved metabolic markers

Months 6-12:

• Cumulative immune restoration
• Potential clinical improvements
• Long-term durability of effects

Cost Analysis

Annual cost estimation (US pricing 2026):

This is an expensive protocol. The cost reflects the premium pricing of clinical-grade senolytic interventions in 2026. Costs will likely decrease as more options become available.

Alternative: The Budget Senolytic Approach

For those unable to access SGLT2 prescribing or premium products, a simpler protocol provides partial benefits:

Budget protocol:

• Fisetin 1000mg x 3 days monthly (~$150-300/year)
• Quercetin 1000mg x 2 days monthly (basic form, ~$50-100/year)
• Metformin 500mg twice daily (off-label, $50-200/year)
• Total: ~$250-600/year

This provides direct natural senolytic effects + some immune surveillance benefits via metformin's pleiotropic effects. Less effective than the full protocol but accessible.

What This Protocol Won't Do

Realistic expectations:

• Will not reverse aging
• Will not eliminate need for healthy lifestyle (this is amplifier, not substitute)
• Will not eliminate all senescent cells
• Will not produce dramatic short-term changes
• Results are partial and gradual

The protocol provides a senolytic intervention based on 2026 evidence — but it's one component of broader longevity strategy, not a standalone solution.

Combining with Other Longevity Interventions

This senolytic stack integrates with broader longevity protocols:

With Cardiovascular Longevity Stack:

• SGLT2 inhibitor already provides cardiovascular benefits
• CoQ10/Astaxanthin/Omega-3 complement the senolytic approach
• Combined cardiometabolic protection

With NAD+ Optimisation:

• NMN or NR support sirtuin function
• SGLT2 inhibitor amplifies SIRT1 activation
• Broad metabolic enhancement

With Hormonal Optimisation:

• Hormonal optimisation important in 50+ population using this protocol
• TRT, HRT, growth hormone optimisation may be relevant
• Senolytic effects amplify hormonal benefits

Tracking Senolytic Effects

Biomarkers to monitor:

Standard inflammation markers:

• hs-CRP (baseline, 3 months, 6 months)
• IL-6 (if available)
• Fibrinogen

Biological age markers (where accessible):

• GlycanAge (immune-glycan-based aging)
• DunedinPACE (rate of aging marker)
• TruDiagnostic / Epigenetic age

Metabolic markers:

• HbA1c
• Fasting insulin
• Body composition (DEXA)

Subjective markers:

• Energy levels
• Exercise recovery
• Cognitive function
• Sleep quality

Track baseline before starting, then 3-month intervals. Patterns over 12-24 months are more informative than single measurements.

The Future of Senolytics

Active development for 2026-2027:

• UBX1325 — Unity Biotechnology's diabetic macular edema senolytic (positive Phase 2b data)
• Senolytic combinations with rejuvenation therapies
• Tissue-specific senolytics — targeting specific organs
• Personalised approaches based on senescent cell load profiling

The field is advancing rapidly. This 2026 protocol reflects current best evidence — it will likely be refined or superseded as new evidence emerges.

Practical Implementation Summary

For experienced longevity practitioners:

• Full 4-component protocol with monitoring
• Adjust based on individual response and biomarkers
• Continue or modify based on 6-month re-evaluation

For those starting senolytic intervention:

• Begin with Fisetin alone (3-day monthly pulses)
• Establish tolerance and routine
• Add Quercetin after 3 months if no issues
• Add SGLT2 inhibitor with physician guidance
• Consider Urolithin A based on budget

For broader longevity audience:

• Even partial implementation (Fisetin alone) provides some senolytic benefit
• Combine with foundational longevity interventions
• Prioritise consistent execution over protocol complexity

Frequently Asked Questions

What is the best senolytic protocol for beginners in 2026?

Start with Fisetin alone — 1000mg daily for 3 consecutive days each month, taken with a fatty meal. After 3 months with no adverse effects, add pulsed Quercetin (1250mg x 2 days monthly, staggered from Fisetin). The SGLT2 inhibitor component requires physician guidance and is best added after establishing baseline tolerance.

How do SGLT2 inhibitors work as senolytics if they don't kill cells directly?

SGLT2 inhibitors downregulate PD-L1 on senescent cells through AICAR upregulation. PD-L1 is an immune checkpoint protein that hides senescent cells from the immune system. By removing this "cloak," SGLT2 inhibitors allow cytotoxic T cells and NK cells to recognise and clear senescent cells naturally — a completely different mechanism from direct senolytics like Quercetin or Fisetin.

Can I use this senolytic stack if I'm under 50?

This protocol is designed for adults 50+ with measurable senescent cell burden. Under 40, senescent cell accumulation is generally low enough that aggressive senolytic intervention has limited benefit and uncertain risk. Between 40-50, consider starting with the budget protocol (Fisetin + Quercetin only) and tracking inflammatory markers before escalating.

How much does the full senolytic stack cost per year?

The full 4-component protocol costs approximately $2,500-$6,800/year including medications, supplements, lab monitoring, and physician consultations. The budget alternative (Fisetin + Quercetin + Metformin) costs roughly $250-600/year and still provides meaningful senolytic activity through direct flavonoid mechanisms.

How do I know if the senolytic protocol is working?

Track hs-CRP and IL-6 at baseline and every 3 months — reductions indicate lower systemic inflammation from senescent cell clearance. Biological age tests (GlycanAge, DunedinPACE, epigenetic clocks) can show rate-of-aging changes over 6-12 months. Subjective markers like energy, recovery, and cognitive clarity often improve within 1-3 months.

Related Research

• SGLT2 Inhibitors: The First Drugs That Reverse Telomere Aging in Humans
• Urolithin A and the Immune System: The 2025 MitoImmune Trial Results
• Berberine vs Metformin: The 2026 Update on Metabolic Longevity

Scientific References

1. Zhang Y, et al. SGLT2 inhibitor henagliflozin and biological aging markers in type 2 diabetes: a randomized controlled trial. Cell Reports Medicine (2025).

2. Katsuumi G, et al. SGLT2 inhibition eliminates senescent cells and alleviates pathological aging. Nature Aging (2024). PMC11257941

3. Yousefzadeh MJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine (2018). PMID 30279143

4. Mayo Clinic Alzheimer's Risk Trial: senolytics in older adults at risk for Alzheimer's disease. eBioMedicine (February 2025). PMID 40006896

5. Liu S, et al. A natural compound revitalizes the aging human immune system (MitoImmune trial). Nature Aging (2025).